Premium Reports
PACS - Acute Care Large Study 2005

PACS - Acute Care Large Study 2005

November 1, 2005

Current Time Inside Cache Tag Helper: 4/14/2021 5:18:36 PM and Model.reportId = 251

The 2005 Large Acute PACS Report is the fifth such report from KLAS (initial report June 2001) regarding PACS vendors and products.

Healthcare Providers,
Want to see more reports?

Not a Provider, contact us for pricing details.

HtmlReportContent Current Time Inside Cache Tag Helper: 4/14/2021 5:18:36 PM and Model.reportId= 251 and Model.HtmlReportContent_LastWriteTimeUtcInTicks=637406508812516527

This report provides an in-depth look at today’s acute care PACS vendors (over 200-bed facilities) and compares their strengths and weaknesses against one another, all PACS vendors and the KLAS HIT average (the average of all Healthcare Information Technology products in the KLAS database). This year's report expands its look at if these products are becoming more enterprise in scope and how well they handle advancements in imaging technologies and capabilities such as 3D, 64-slice CT, Digital Mammography, etc.

The report features 12 vendor products: Agfa IMPAX, AMICAS PACS, DR Systems Dominator, Emageon, Fuji Synapse, GE Centricity PACS, IDX ImageCast, Kodak DirectView PACS, McKesson Horizon Medical Imaging, Philips EasyAccess PACS, Philips (Stentor) iSite PACS, and Siemens SIENET PACS.

An Addendum features seven additional vendors: Cerner Millennium ProVision PACS, Dynamic Imaging IntegradWeb PACS, Intelerad IntelePACS, Merge eMed FUSION PACS, Merge eMed Matrix, Misys PACS, and StorCOMM AccessNET PACS.

 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2021 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.